S-1/A: ReShape Lifesciences Eyes $4.45 Million in Unit Offering Amidst Merger Plans

ReShape Lifesciences is undertaking a best-efforts unit offering to raise capital while navigating a pending merger and asset sale.

Summary

• ReShape Lifesciences is offering up to 1,326,260 units, each consisting of one share of common stock or one pre-funded warrant and one warrant, at an assumed price of $3.77 per unit.
• The offering is on a best-efforts basis, with Maxim Group LLC acting as the exclusive placement agent.
• The company is also offering pre-funded warrants as an alternative for purchasers who would exceed beneficial ownership limits.
• The warrants will be exercisable upon stockholder approval and have a potential one-time reset of the exercise price.
• ReShape intends to use the net proceeds for general corporate purposes, including expenses related to the proposed merger with Vyome Therapeutics, Inc. and asset sale to Ninjour Health International Limited.
• The company's stock is traded on the Nasdaq Capital Market under the symbol RSLS.
• The offering is expected to be completed no later than one business day following the commencement of sales.
• The company has engaged Maxim Group LLC as the exclusive placement agent in connection with this offering.
• The placement agent has agreed to use its reasonable best efforts to solicit offers to purchase the securities offered by this prospectus.
• The placement agent is not purchasing or selling any of the securities we are offering, and the placement agent is not required to arrange the purchase or sale of any specific number or dollar amount of securities.
• The company has agreed to pay the placement agent, the placement agent fees set forth in the table below and to provide certain other compensation to the placement agent.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is pursuing growth strategies and has new products, the offering is on a best-efforts basis and there are risks associated with the merger and the company's financial condition.

Positives

• The offering provides ReShape with potential capital to fund operations and merger-related expenses.
• The warrants offer potential upside for investors if the stock price increases after stockholder approval.
• The pre-funded warrants provide flexibility for investors with ownership limitations.

Negatives

• The offering is on a best-efforts basis, so the actual amount raised may be substantially less than the total maximum offering amount.
• There is no established trading market for the warrants and pre-funded warrants.
• The warrants are not exercisable until stockholder approval is obtained, and may never become exercisable.
• The company has broad discretion over the use of the net proceeds.
• Investors will experience immediate dilution in the net tangible book value per share.
• The company's stock price has been volatile and is likely to be volatile in the future.

Risks

• Management will have broad discretion as to the use of the net proceeds from this offering, and we may not use these proceeds effectively.
• This is a best efforts offering, and no minimum number or dollar amount of securities is required to be sold, and we may not raise the maximum amount we are offering.
• You will experience immediate dilution in the net tangible book value per share of the Common Stock you purchase, and may experience additional dilution in the future.
• There is no public market for the Warrants or Pre-funded Warrants being offered by us in this offering.
• If the Warrants are exercised by way of an alternative cashless exercise, especially after the reset date stockholders may suffer substantial dilution.
• The Warrants are not exercisable unless and until Warrant Stockholder Approval is obtained from our stockholders. Further, even if we obtain Warrant Stockholder Approval, the Warrants may only be exercisable for a limited period of time.

Future Outlook

The combined company intends to change its name to Vyome Holdings, Inc. and will focus on Vyomes business of advancing the development of its immunoinflammatory assets and on identifying additional opportunities between the world-class Indian innovation corridor and the U.S. market.

Management Comments

• Under this new leadership, our company has pivoted its business strategy with the intent of helping to ensure growth and profitability.
• This first growth pillar remains, in our companys opinion, paramount for ReShape to deliver shareholder value and, ultimately, profitability.

Industry Context

The announcement is relevant to the medical device and pharmaceutical industries, particularly in the context of weight-loss solutions and metabolic disease treatments. It also touches on the trend of mergers and acquisitions in the healthcare sector.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or competitors.
• It focuses on the company's own strategies and product portfolio.

Stakeholder Impact

• Shareholders may experience dilution.
• Employees face uncertainty due to potential changes after the merger and asset sale.
• Customers may benefit from new products and services if the merger and development plans are successful.
• Suppliers may be affected by changes in the company's operations and relationships.

Next Steps

• Seek stockholder approval for the warrant exercise.
• Complete the merger with Vyome Therapeutics, Inc. and asset sale to Ninjour Health International Limited.
• Continue to develop and commercialize innovative products and services.

Key Dates

Keywords

offering, warrants, pre-funded warrants, common stock, merger, placement agent, ReShape Lifesciences, Vyome, Ninjour, RSLS